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Marc G. Vervloet, MD, PhDc, Gerjan Navis, MD, PhDa, Danilo Fliser, MD, PhDb, Gunnar H. Heine, MD, PhDb,
Martin H. de Borst, MD, PhDa,
∗
Abstract
Fibroblast growth factor 23 (FGF-23) rises progressively in chronic kidney disease and is associated with adverse cardiovascular
outcomes. FGF-23 putatively induces volume retention by upregulating the sodium-chloride cotransporter (NCC). We studied
whether, conversely, interventions in volume status affect FGF-23 concentrations.
We performed a post hoc analysis of 1) a prospective saline infusion study with 12 patients with arterial hypertension who received
2L of isotonic saline over 4 hours, and 2) a randomized controlled trial with 45 diabetic nephropathy (DN) patients on background
angiotensin-converting enzyme -inhibition (ACEi), who underwent 4 6-week treatment periods with add-on hydrochlorothiazide
(HCT) or placebo, combined with regular sodium (RS) or low sodium (LS) diet in a cross-over design. Plasma C-terminal FGF-23 was
measured by ELISA (Immutopics) after each treatment period in DN and before and after saline infusion in hypertensives.
The patients with arterial hypertension were 45±13 (mean±SD) years old with an estimated glomerular ﬁltration rate (eGFR) of 101
±18mL/min/1.73m2. Isotonic saline infusion did not affect FGF-23 (before infusion: 68 median [ﬁrst to third quartile: 58–97] relative
unit (RU)/mL, after infusion: 67 [57–77]RU/mL, P=0.37). DN patients were 65±9 years old. During ACEi+RS treatment, eGFR was
65±25mL/min/1.73m2 and albuminuria 649mg/d (230–2008mg/d). FGF23 level was 94 (73–141)RU/mL during ACEi therapy.
FGF-23 did not change signiﬁcantly by add-on HCT (99 [74–148]RU/mL), LS diet (99 [75–135]RU/mL), or their combination (111
[81–160]RU/mL, P=0.15).
Acute and chronic changes in volume status did not materially change FGF-23 in hypertensive patients and DN, respectively. Our
data do not support a direct feedback loop between volume status and FGF-23 in hypertension or DN.
Abbreviations: eGFR = estimated glomerular ﬁltration rate, CKD = chronic kidney disease, CKD-EPI = Chronic Kidney Disease
Epidemiology Collaboration group, DN = diabetic nephropathy, FGF-23 = ﬁbroblast growth factor 23, HCT = hydrochlorothiazide, ln
= natural logarithm, LS = low sodium, NCC = sodium-chloride cotransporter, RAAS = renin–angiotensin–aldosterone system, RS =
regular sodium, RU = relative unit.
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The phosphaturic hormone ﬁbroblast growth factor 23 (FGF-23)
is a central regulator of calcium-phosphate metabolism. In
moderate-to-severe chronic kidney disease (CKD), FGF-23
concentrations progressively increase in an attempt to keep
phosphate balance.[1] More recently, a higher concentration of
FGF-23 in CKD patients has been linked with an increased risk of
cardiovascular events, particularly with decompensated heart
failure, which in CKD is often caused by hypervolemia (as
reviewed in Ref. [2]). Similar associations between plasma FGF-23
concentrations and the incidence of decompensated heart failure
were found among individuals without overt CKD.[3–5]
In line, animal experiments suggest that FGF-23 may directly
induce left ventricular hypertrophy via the calcineurin-NFAT
pathway.[6,7] Yet, the role of FGF-23 in cardiovascular disease in
patients without advanced CKD is subject of debate,[8,9] and other
pathophysiological pathways may be involved.[10] Notably, in
addition to the proposed direct effects of FGF-23 on the
myocardium, volume overload could contribute to the association
between increased FGF-23 and decompensated heart failure
observed in cohort studies. This hypothesis is fueled by recent
experimental data, which suggest that FGF-23 may activate the
sodium-chloride cotransporter (NCC) in thedistal tubule, inducing
volume expansion, hypertension, and subsequently left ventricular
hypertrophy.[11] The diuretic hydrochlorothiazide (HCT), which
inhibits theNCCin the distal tubule, prevented thesepresumedoff-
target effects. These observations add to previously documented
independent associations between FGF-23 andmarkers of volume
status,[12] and could at least partly explain the previously observed
association between a higher FGF-23 level and an impaired
antiproteinuric response to volume depletion.[13] Conversely,
recent data suggest that changes in volume status may modulate
FGF-23 concentrations at least in hemodialysis.[14] This suggests
the presence of a feedback loop, where FGF-23 increases volume
load, and an increase in volume may reduce FGF-23. Vice versa, a
reduction in volume load may in turn increase FGF-23. In the
present study, we investigated the effect of interventions in volume
status on FGF-23 in 2 independent settings. We ﬁrst analyzed the
acute effects of intravenous volume loading on plasma FGF-23 in
12 hypertensive individuals without overt CKD. Second, we
investigated the chronic impact of dietary sodium restriction and
HCT therapy on plasma FGF-23 in patients with diabetic CKD
during standardized angiotensin-converting enzyme inhibition
(ACEi). To expand knowledge on the hypothesized bidirectional
relationship between FGF-23 and volume regulation, we analyzed
among the same patients the extent by which FGF-23 plasma
concentrations predict the antiproteinuric response to dietary
sodium restriction and HCT therapy.2. Materials and methods
2.1. Study design and measurements
To investigate the effects of acute volume load on FGF-23 plasma
concentrations, we analyzed 12 outpatients with arterial
hypertension but without overt CKD (deﬁned as an estimated
glomerular ﬁltration rate [eGFR]<60mL/min/1.73m2) who
received an infusion of 2L isotonic saline in 4 hours. Ethyl-
enediaminetetraacetic acid-plasma samples to measure FGF-23
concentrations were obtained immediately before and after
administration of the infusion. The acute volume expansion
study was approved by the local Medical Ethical Committee in
Saarland, Germany.2Furthermore, to investigate the long-term effects of modiﬁca-
tions in volume status on FGF-23, we performed a post hoc
analysis on a randomized, placebo-controlled, double-blinded
cross-over intervention trial addressing the effects of sodium
restriction and thiazide diuretic treatment during background
ACEi. The original study protocol has been described previously
(Dutch trial registry number 2366).[15] Brieﬂy, 45 patients with
type 2 diabetes and diabetic nephropathy (DN) were included.
DN was deﬁned as albuminuria >30mg/d, urinary albumin
excretion >20mg/L, or urinary albumin–creatinine ratio >2.5
mg/mmol for men and >3.5mg/mmol for women. Patients had a
creatinine clearance >30mL/min and did not have signs of
another primary renal disease. Main exclusion criteria were
presence of type 1 diabetes, renovascular disease, a cardio- or
cerebrovascular event<3 months ago, overt hyperkalemia (>6.0
mmol/L) or nephrotic syndrome, renal transplant recipients, use
of immunosuppressants, blood pressure >180/100mm Hg, and
contraindications to the use of lisinopril or HCT. All patients
were titrated to maximum-dose ACEi (lisinopril 40mg/d), with
discontinuation of other rennin–angiotensin–aldosterone system-
blockers/diuretics and stable dose of other antihypertensives.
Patients underwent 4 subsequent 6-week treatments periods in
randomorder: HCT (50mg/d) or placebo, combinedwith either a
sodium-restricted diet (targeting 50mmol a day or ∼3g NaCl/d)
versus a liberal sodium diet. Patients had 1 or 2 dietary counseling
sessions with a dietitian and received a list with the sodium
content of general used food products in the Netherlands.
After each treatment period, measurements were performed,
blood samples were taken by venipuncture, and 24-hour urine
was collected. The study was conducted in accordance with the
Declaration of Helsinki and approved by the Medical Ethical
Committee of the University Medical Center Groningen (proto-
col number 2010/288).2.2. Laboratory measurements
For these analyses, we determined FGF-23 by human FGF-23
enzyme-linked immunosorbent assay directed against the
carboxy-terminus (Immutopics Inc, San Clemente, CA: low
cutoff 1.5 relative unit [RU]/mL; high cutoff 1500RU/mL, intra-
assay and interassay coefﬁcients of variation of<5% and<16%,
respectively[16]) in EDTA plasma samples obtained at baseline
and after each treatment. Blood samples were stored at 80 °C
and analyzed in batch. For 37 patients, EDTA-plasma was
available for FGF-23 measurements at all 4 treatment periods.
Blood and urinary electrolytes were measured by RocheModular
multianalyzer (Roche Diagnostics, Mannheim, Germany). Albu-
minuria was measured in 24-hour urine samples in single-batch
by benzethonium chloride-based turbidimetric assay. Renin
and aldosterone were measured with a chemiluminescence
immunoassay (LIASON Aldosterone and LIASON Direct
Renin, DiaSorin Deutschland GmbH, Dietzenbach, Germany).
We calculated eGFR with the creatinine-based Chronic Kidney
Disease Epidemiology Collaboration group equation.[17]2.3. Statistical analyses
Statistical analyses were performed with SPSS Statistics 22 (IBM
Corp., Armonk, NY). Data are reported as mean± standard
deviation or median (ﬁrst to third quartile), as appropriate,
after assessing normality by plotting the data. A P value <0.05
was considered to reﬂect statistical signiﬁcance. Statistical







Age, y 45±13 65±9
Male gender, n (%) 4 (33) 38 (84)
BMI, kg/m2 28±4 32±5
eGFR, mL/min/1.73m2 101±18 65±25
Proteinuria, g/d 0.1 (0.1–0.2) 1.1 (0.5–3.2)
Albuminuria, mg/d 11 (7–14) 649 (230–2008)
Systolic blood pressure, mm Hg 178±33 147±16
Diastolic blood pressure, mm Hg 104±18 82±10
Creatinine clearance, mL/min 113±27 101±47
Sodium excretion, mmol/24h 183±61 224±76
HbA1c, % N/A 7.1±0.8
Diabetes duration, y N/A 11.8±7.6
Macrovascular disease, n (%) 1 (8) 21 (47)
Coronary artery disease, n (%) 1 14 (31)
Stroke (CVA, TIA) 0 6 (13)
Peripheral artery disease, n (%) 0 7 (16)
Antihypertensives
ACEi, n (%) 1 (8) 45 (100)
Beta blocker, n (%) 0 27 (60)
Humalda et al. Medicine (2016) 95:46 www.md-journal.comrenin concentrations before and after sodium-chloride infusion
were assessed by Wilcoxon Signed Rank test. In the DN cohort,
data were natural log (ln)-transformed, as appropriate, and were
compared by the Friedman test for dependent variables in case of
skewed distribution. Normally distributed dependent variables
were compared by one-way ANOVA with repeated measures.
Multivariable regression analysis was performed to investigate
the association of baseline FGF-23 with ln-transformed residual
proteinuria after each of the 4 individual treatment periods in the
DN cohort. We ﬁrst assessed the relationship between FGF-23 as
independent and residual proteinuria as dependent variable in
univariate regression analysis as described earlier.[13] Subse-
quently, we studied the relationship between FGF-23 and
residual proteinuria at the end of each treatment period in a
model adjusted for “baseline” proteinuria, that is, proteinuria
during regular sodium (RS) diet and placebo. Finally, we further
adjusted for creatinine clearance, a potential confounder of the
relation between FGF-23 and antiproteinuric response, and
repeated these analyses with eGFR. We constructed multiplica-
tive interaction terms for FGF-23 and proteinuria, creatinine
clearance, and eGFR, respectively.Alpha blocker, n (%) 4 (33) 4 (9)
Calcium-channel blocker, n (%) 5 (42) 27 (60)
Diuretic therapy 0 0
Vitamin D treatment, n (%) 0 3 (7)
Phosphate binder treatment, n 0 0
ACEi = angiotensin-converting enzyme inhibitor, BMI = body mass index, CVA = cerebrovascular
accident, DN = diabetic nephropathy, eGFR = estimated glomerular ﬁltration rate, HbA1c = glycated
hemoglobin, HT = arterial hypertensive, TIA = transient ischemic attack.
Figure 1. Effect of 2L of saline infusion on ﬁbroblast growth factor 23
concentrations after 4 hours. P value reﬂects Wilcoxon Signed Rank test. RU =
relative unit.3. Results
3.1. Volume loading and FGF-23 concentrations in
hypertension
We ﬁrst studied the effect of intravenous sodium loading on
plasma FGF-23 in 12 hypertensive individuals without CKD
stage 3 or higher, that is, with eGFR>60mL/min/1.73m2. These
patients were 45±13 years old and had normal renal function;
further characteristics are presented in Table 1. Median FGF-23
plasma concentrations at baseline were 68 (58–97)RU/mL. The
infusion of 2L isotonic saline in 4 hours did not change FGF-23
concentrations (P=0.37, Fig. 1). Plasma renin concentration did
not signiﬁcantly change (from 4.5 [1.3–14.4] to 1.8 [0.8–9.6]pg/
mL, P=0.24), whereas aldosterone decreased signiﬁcantly from
86 (70–140) to 58 (0–64)pg/mL as expected (P=0.003).
3.2. Volume reduction and FGF-23 concentrations in
diabetic nephropathy
Baseline characteristics of the study population are depicted in
Table 1.The DN patients were 65±9 years old with a mean eGFR
of65±25mL/min/1.73m2andproteinuriaof 1.1g/d (0.5–3.2g/d).
During ACEi monotherapy and RS diet, plasma FGF-23
concentration was 94 (73–141)RU/mL. Six weeks of treatment
with add-on HCT did not signiﬁcantly change the FGF-23 plasma
concentration (posttreatment FGF-23 levels are presented in
Table 2). Similarly, 6weeksof add-on low-sodium (LS) diet did not
affect FGF-23plasmaconcentration.Combination therapyofboth
LS diet and HCT, in addition to ACEi treatment, resulted in a
nonsigniﬁcant increase in FGF-23 to 111 (81–160)RU/mL (P=
0.15). Treatment with only HCT or a LS diet lowered proteinuria,
as reported before,[11] with a stronger proteinuric reduction after
combination therapy. Similarly, both individual and combined
interventions inﬂuenced volume status, as reﬂected by a reduction
in body weight (Table 2). Only combination therapy resulted in a
decrease in creatinine clearance, whereas HCT treatment in itself
also reduced eGFR.[11] Serum calcium and phosphate and urinary
phosphate excretion did not differ across treatment periods
(Table 2). Urinary calcium excretion dropped from 1.6 (0.9–3.3)
mmol/d during RS diet and background ACEi therapy to 1.03(0.4–2.6)mmol/d with add-on HCT, 1.3 (0.6–2.7)mmol/d with
add-on LS diet and to 0.7 (0.4–1.7)mmol/d with combination
therapy, respectively (P<0.001).3.3. FGF-23 and antiproteinuric response to volume
interventions in DN
The residuals of proteinuria were normally distributed after ln-
transformation. In univariable regression analysis, FGF-23 was
Table 2
Clinical parameters during different treatment periods.
Variables Unit ACEi+RS ACEi+HCT+RS ACEi+LS ACEi+HCT+LS Reference value P
Clinical and general laboratory parameters
Proteinuria g/d 1.1 (0.5–3.2) 0.7 (0.5–1.7) 0.7 (0.4–2.2) 0.5 (0.3–1.3) <0.3 <0.001
Proteinuria reduction % – 27 (38) 28 (26) 46 (29) <0.001
Proteinuria/creatinine g/mmol 0.07 (0.04–0.22) 0.04 (0.03–0.14) 0.05 (0.03–0.18) 0.03 (0.02–0.10) <0.001
Albuminuria mg/d 649 (230–2008) 342 (215–1205) 307 (147–1072) 261 (125–878) <30 <0.001
Systolic blood pressure mm Hg 147±16 135±16 141±16 129±14 <140 <0.001
SBP reduction % – 7.6±8.0 3.4±8.6 11.2±8.3 <0.001
eGFR mL/min/1.73m2 65±25 60±27 65±27 59±25 <0.001
Creatinine clearance mL/min 101±47 97±47 99±48 88±42 0.004
Body weight kg 102±18 100±18 99±18 98±18 <0.001
24-h sodium excretion mmol/d 224±76 224±88 148±65 164±71 100–250 <0.001
Plasma sodium mmol/L 140.3±3.1 139.6±3.2 139.7±3.3 138.0±3.7 135–145 <0.001
Mineral metabolism parameters
FGF-23 RU/mL 94 (73–141) 99 (74–148) 99 (75–135) 111 (81–160) <125 0.15
Serum phosphate mmol/L 1.00±0.15 1.01±0.14 1.01±0.14 1.04±0.18 0.70–1.50 0.31
24h phosphate excretion mmol/d 25.8±11.4 25.6±10.4 22.9±9.0 23.2±9.7 <48.0 0.13
Serum calcium mmol/L 2.33±0.11 2.34±0.10 2.32±0.10 2.36±0.11 2.20–2.60 0.17
24h calcium excretion mmol/d 1.6 (0.9–3.3) 1.0 (0.4–2.6) 1.3 (0.6–2.7) 0.7 (0.4–1.7) 2.5–7.5 <0.001
ACEi = angiotensin-converting enzyme inhibitor, eGFR = estimated glomerular ﬁltration rate, FGF-23 = ﬁbroblast growth factor 23, HCT = hydrochlorothiazide, RS = regular sodium, SBP = systolic blood
pressure.
Humalda et al. Medicine (2016) 95:46 Medicinesigniﬁcantly associated with residual proteinuria during RS diet
and add-on HCT. The association was not signiﬁcant during LS
diet, but was again signiﬁcant for the combination therapy of
HCT with LS diet (Table 3, model 1). In multivariable regression
analysis, as expected, baseline proteinuria during RS diet
outperformed FGF-23 as a correlate of proteinuria after add-
on HCT (Table 3, model 2). Also during LS diet, FGF-23 was not
signiﬁcantly associated with the antiproteinuric response when
adjusted for baseline proteinuria (Table 3). FGF-23 plasma
concentrations were also not signiﬁcantly correlated with the
antiproteinuric response in the combination therapy group.
When we used eGFR instead of creatinine clearance, this did not
materially change the results. Invocation of multiplicativeTable 3
Multivariable regression analysis for ln residual proteinuria after diffe
Treatment period Model Determinant B


















FGF-23 and proteinuria were ln-transformed. All determinant variables are under ACEi+ regular sodium die
unstandardized coefﬁcient, CrCl = creatinine clearance, FGF-23 = ﬁbroblast growth factor 23, HCT = hyd
coefﬁcient.
4interaction terms did not demonstrate interaction between
FGF23 and proteinuria, creatinine clearance, or eGFR, respec-
tively (all P interaction >0.1).4. Discussion
In the present study, we tested the hypothesis that volume
intervention would impact FGF-23 concentrations in 2 indepen-
dent settings, namely in patients with hypertension with
preserved renal function and in DN patients. Such ﬁnding would
support the existence of a negative feedback loop, where volume
expansion could suppress FGF-23, while volume depletion could
increase FGF-23 as counterpart regulatory response to FGF-23-rent treatments.
95% CI B Standardized b P R2
0.133–1.030 0.412 0.01 0.17
0.016–0.538 0.196 0.04 0.75
0.508–0.818 0.790 <0.001
0.046 to 0.513 0.165 0.10 0.75
0.491–0.808 0.775 <0.001
0.005 to 0.002 –0.088 0.37
0.124 to 1.035 0.264 0.12 0.07
0.233 to 0.291 0.017 0.82 0.83
0.773–1.083 0.906 <0.001
0.192 to 0.364 0.050 0.53 0.84
0.788–1.103 0.923 <0.001
0.002 to 0.006 0.094 0.24
0.024–1.031 0.343 0.04 0.12
0.132 to 0.572 0.143 0.21 0.61
0.460–0.878 0.733 <0.001
0.109 to 0.648 0.175 0.16 0.62
0.470–0.899 0.749 <0.001
0.003 to 0.007 0.093 0.45
t conditions. 95% CI = 95% conﬁdence interval, ACEi = angiotensin-converting enzyme inhibitor, B =
rochlorothiazide, ln = natural log-transformed, LS = low-sodium diet, Standardized b = standardized
[13]
Humalda et al. Medicine (2016) 95:46 www.md-journal.cominduced sodium retention. However, neither acute volume
expansion nor chronic volume depletion changed FGF-23
concentrations.
Cardiovascular disease is highly prevalent in patients with
CKD and the main cause of mortality in patients with CKD.
Increased FGF-23 plasma concentrations are known to be
independent predictors of adverse cardiovascular outcome in
patients with CKD and in individuals with normal renal
function.[3,18–21] In these observational studies, FGF-23 was
more compellingly associated with acute heart failure than with
atherosclerotic events. Given the consistent associations between
FGF-23 and markers of volume status in previous studies,[22–24]
and the implicated role for FGF-23 in volume homeosta-
sis,[11,13,22] we sought to investigate whether, conversely, an
acute increase in volume status inﬂuences FGF-23 concentra-
tions. We found that acute expansion of extracellular volume by
sodium-chloride infusion did not reduce FGF-23 concentrations
in patients with arterial hypertension.
This negative result may be explained by the short interval
between the volume intervention and the FGF-23 measurement.
In comparison, the increase of FGF-23 following dietary
phosphate intake takes multiple hours to develop.[25] On the
other hand, acute changes in volume status such as cardiogenic
shock are known to suddenly increase FGF-23 to far higher
concentrations within a day and even on admission, respective-
ly.[26] Second, we also assessed the effects of chronic
interventions, after homeostatic readjustment could have taken
place. The DN patients had FGF-23 concentrations that are
typically observed in patients with mildly impaired renal
function. The volume-depleting interventions of dietary sodium
restriction and HCT did not signiﬁcantly increase FGF-23
concentrations in these patients. Intensiﬁcation of treatment
with HCT or a LS diet did not change FGF-23 concentrations.
This is in line with our earlier observations in nondiabetic
proteinuric CKD patients, where LS diet or add-on angiotensin-
receptor blockade did not increase FGF-23 concentrations.[13]
However, combination of LS diet with HCT did show a small
but nonsigniﬁcant increase in FGF-23 concentrations. This small
increase is probably caused by the concomitant drop in renal
function, as FGF-23 starts to increase markedly when renal
function drops below ∼60mL/min/1.73m2.[1] In that perspec-
tive, a greater increase in FGF-23 concentrations may have been
expected. Of note, the observed decrease in renal function is
considered an indicator of therapeutic efﬁcacy, since such effect
has been associated with long-term preserved renal function.[27]
Our results suggest that the relationship between FGF-23 and
volume status is not bidirectional in patients with mild-to-
moderate CKD and in patients with normal renal function. The
effects of FGF-23 on volume status as proposed by others may be
considered an “off-target effect” of FGF-23, rather than that
volume status triggers a FGF-23 response in CKD patients with
mildly to moderately impaired renal function. In the setting of
hemodialysis, on the other hand, the more extreme changes in
volume status may result in a stronger correlation with FGF-23
concentrations.[14]
Since both dietary sodium restriction and diuretic therapy
reduced body weight and residual proteinuria, and volume
depletion is known to potentiate the antiproteinuric response,[28]
we subsequently analyzed the relationship between FGF-23 and
residual proteinuria. However, we could not demonstrate a
strong relation of FGF-23 with the antiproteinuric response.
This ﬁnding seems at variance with our earlier report, where a
high FGF-23 concentration was correlated with an impaired5antiproteinuric response to LS diet. In the present study, the
correlation of FGF-23with residual proteinuria was lost whenwe
adjusted for renal function. An explanation may be that in the
present study there were more patients with lower proteinuria
levels (13 of 45 had proteinuria<0.5g/d, whereas in our previous
study only 5 of 47 had proteinuria<0.5g/d). Patients with higher
proteinuria reabsorb sodium more avidly,[29] which makes
sodium restriction a particular helpful strategy in these patients
(as reviewed elsewhere[30]). In addition, in the present study, the
lower proteinuria levels before therapy intensiﬁcation may have
precluded the identiﬁcation of determinants of proteinuria after
therapy intensiﬁcation in our regression analyses. Also, the
smaller sample size likely led to less statistical power to detect an
effect. Although nonsigniﬁcant, our present ﬁndings in patients
with DN point toward a similar direction of effects as in our
earlier report.
Strengths of our study include the use of a randomized
controlled cross-over trial where we could assess 3 treatment
combinations in the same subjects targeting volume status.
Further, we performed a prospective experiment in patients who
received intravenous sodium-chloride. FGF-23 plasma concen-
trations were determined using the same assay, enabling a
comparison of the effects. Limitations of the study that deserve to
be mentioned are the post hoc nature of the analysis in DN study
and the small number of patients increasing the chance of a type II
error (false negative ﬁnding), particularly in the infusion
experiment. Therefore, larger experiments are needed to conﬁrm
our ﬁndings. Since phosphate intake was not controlled during
the studies, changes in dietary phosphate might have inﬂuenced
the results, althoughwe did not observe any differences in urinary
phosphate excretion or serum phosphate in response to volume
interventions. In addition, in the infusion experiment, we
investigated patients with arterial hypertension, who could have
suffered from subclinical volume retention, which could have
prevented a signiﬁcant response of FGF-23 levels to acute
expansion of extracellular volume.
Further, the interaction between FGF-23 and volume status
appears to be stronger in proteinuric CKD, and proteinuria is a
strong correlate of FGF-23 concentration,[31] suggesting that
the effects of ﬂuid administration should be assessed in arterial
hypertensive patients with proteinuria. The DN patients were
all on background ACEi therapy. This may have altered the
FGF-23–klotho–vitamin D axis, uncoupling the effect of
increased renin expression by angiotensin 2 on FGF-23
concentrations, so that an additional effect of sodium
restriction or HCT on FGF-23 plasma concentrations might
have been precluded.[32]
In conclusion, we could not demonstrate any effect of acute or
chronic volume interventions on plasma FGF-23 concentrations
in patients with DN or hypertension and normal renal function,
respectively. Our data do not support a direct feedback
mechanism of volume status on FGF-23. Future studies may
address whether lowering of FGF-23 by other means in patients
prone to volume retention improves outcomes.References
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